by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Email this page to a friend
Search this issue
Index - jump to page or section
Archive - view past issues
GP Week : Issue 232
Jean Boulle Medtech Ltd, a Jean Boulle Group medical technology company and founding investor of Tendyne Holdings, Inc, is pleased to announce that Abbott Laboratories has closed its acquisition of Tendyne. Abbott thereby acquires the remaining shares of Tendyne that it does not already own for US$250 million plus potential future payments tied to regulatory milestones. This acquisition culminates a relationship that began when Jean Boulle Medtech welcomed Abbott as an early strategic investor in Tendyne. Jean Boulle Medtech worked with Tendyne's most recent investor, Apple Tree Partners, in helping to complete the transaction. Tendyne has developed a heart valve specifically designed to address the complex mitral anatomy of functional, degenerative and mixed etiology mitral regurgitation – a disorder in which the mitral valve on the left side of the heart does not close properly. Left untreated, mitral regurgitation can lead to heart failure and death. Many millions of people, in the United States alone, will benefit from mitral valve replacement. The Tendyne mitral valve is literally placed inside a beating heart via a transcatheter and does not require open-heart surgery. There is therefore no need to stop the heart beating, as has been the case up till now. A catheter enters the bottom of the heart through a small tube inserted in a small incision in the patient’s chest. The physician uses the tube to deploy the valve and positions it so that it rests over the heart's existing mitral valve. It is then anchored securely in place by an adjustable tether. The valve is fully retrievable, totally repositionable and is sewn onto a Nitinol frame. Nitinol is a superelastic nickel and titanium "shape memory alloy" whose flexibility eases implantation, but regains its original shape when it returns to a patient’s normal body temperature. The Tendyne valve’s nickel/titanium alloy composition is derived from a corporate history of making major discoveries which Tendyne has in common with three other Jean Boulle Group Companies. The first founded Diamond Fields Resources, Inc, and discovered one of the world's largest and richest nickel deposits in Voisey's Bay, Canada. The second founded Titanium Resources Group Ltd and restarted and rediscovered one the world's largest and richest titanium mines in Sierra Leone. The third, World Titanium Resources discovered and is developing one of the world’s largest and highest- grade titanium deposits, in South Western Madagascar. The Tendyne valve is currently undergoing clinical trials in the United States, Great Britain and Australia as part of a multi- centre global feasibility study on the safety and performance of the Tendyne valve in patients with symptomatic mitral regurgitation of degenerative or functional etiology, some of whose medical conditions would otherwise make them inoperable. Initial patient results have been positive with most, if not all, patients having no mitral valve regurgitation after being discharged from hospital within a few days of surgery. The Tendyne valve has been successfully implanted in patients at such internationally renowned medical institutions as the Royal Brompton Hospital in London, England; St Vincent's Hospital in Sydney, Australia; and The Minneapolis Heart Center at Abbott Northwestern Hospital in Minneapolis, Minnesota. Other prestigious medical institutions in the expanding universe of Tendyne clinical trials include Baylor Heart and Vascular Center, Dallas, Texas; Cleveland Clinic Foundation, Cleveland, Ohio; St. Francis Hospital, Roslyn, New York; and Oslo University Hospital, Oslo, Norway. Members of Tendyne's Medical Advisory team include : Mark Gillinov MD, The Cleveland Clinic Heart Center; Paul Grayburn MD, Baylor Jack and Jane Hamilton Heart and Vascular Hospital; Lucian Lozonschi MD, Associate Professor of Cardiac Surgery, University of Wisconsin School of Medicine and Public Health; Georg Lutter MD, University of Kiel, Eduardo de Marchena MD, Professor of Medicine and Surgery and Associate Dean for International Medicine, University of Miami Health System; Mark Reisman MD, Clinical Professor of Medicine, University of Washington; Murat Tuzcu MD, The Cleveland Clinic; and Horst Sievert MD. Jean Boulle Medtech is a subsidiary of the medical division of the Jean Boulle Group of Companies. This division invests in medical technology and includes companies such as Jean Boulle Medtech (Ocudyne) Ltd., which is the founding investor in a project exploring the cause of, and a cure for, aged-related macular degeneration, a leading cause of blindness around the world. More iNForMatioN: Jean Boulle Group Ms Audrey Richardson email@example.com WEB: jeanboullegroup.com or Wayne Malouf, in Dallas, Texas Ph: +1 214 691 9000 firstname.lastname@example.org Jean Boulle Group – Us$250m + Abbott Laboratories Acquisition of Tendyne Holdings 11 GPWEEK.com // 11 GPWEEK.com // PARTNERS: F1 >>> news gutierrez confirmed at haas It was perhaps the worst kept secret in Formula 1; esteban Gutierrez will join haas for the 2016 season. The 24-year-old was confirmed at the all-new team over the course of the Mexican Grand Prix, his home race, completing the American squad's lineup for 2016. Following the Japanese Grand Prix the team revealed Romain Grosjean as its lead driver. Gutierrez has sat out the current season where he has worked as Ferrari's reser ve driver, making him an ideal prospect for Haas. He had been one of a number of drivers linked with the drive. Fellow Ferrari employee Jean-Eric Vergne was tipped with a move while Nico Hulkenberg also had his name mentioned in connection with the drive. "I got to know Esteban through our relationship with Ferrari, and after looking at the success he’s had to earn his role there, it became clear he was an excellent choice for our race team," reasoned team owner Gene Haas. “He’s young and hungry, but not inexperienced. His two years running a full F1 schedule has given him some very good race experience, and having spent this season at Ferrari as their third driver allowed him to see firsthand the methodology that makes Ferrari such a power in Formula 1. “We’re very happy to have Esteban as a part of our race team. Between him and Romain, we have a strong driver lineup that will help us develop our car and, ultimately, score some points in our inaugural season.” “This is an excellent opportunity that builds on my time with Ferrari and I will make the most of it,” added Gutierrez. "Gene Haas believes in me and I believe in how he’s going about competing in Formula One. To have a race seat in a competitive car with Ferrari power is very special, and I appreciate the faith he has in me. I trust we’ll be able to achieve great things together.” “All along we said we were looking for experienced drivers, and we have that with Romain and Esteban,” said team pincipal Guenther Steiner. “Romain has more starts, but Esteban has a deep knowledge of Ferrari and how they do things. He’s learned from the best in his role as their third driver, which means he knows how they’ve developed their current cars. He’s been a big part of that and he’ll be a big part in the development of our cars at Haas.”